The drug was shown to decrease a number of inflammatory proteins. Because inflammatory proteins play a critical role in inflammation and drive the inflammatory response to disease, controlling these proteins may prevent or slow disease progression.
The study will enroll up to 72 healthy volunteers and assess safety and tolerability of the treatment.
“MLN0415, a new molecule discovered by Millennium scientists, selectively targets a key pathway involved in inflammatory response, which makes it an attractive product candidate for preventing or delaying disease progression,” said Nancy Simonian, senior vice president of Clinical, Medical and Regulatory Affairs at Millennium. “We continue to advance novel molecules into the clinic and this study is part of a larger inflammatory development program that includes five product candidates.”